illumiSonics develops PARS® advanced optical imaging systems
for a wide range of pre-clinical and clinical applications.
for a wide range of pre-clinical and clinical applications.
PARS® is a revolutionary microscope for in-situ diagnostics. It is:
|
PARS® offers ...
|
PARS® Histology will
|
IMPROVE CANCER
PATIENT OUTCOMES PARS® allows diagnostics during surgery, which leads to more precise resections and avoids repeat surgeries.
|
ENABLE COST SAVINGS
PARS® reduces operating room utilization and improves throughput for clinical labs.
|
ENHANCE THE
DIAGNOSTICS WORKFLOW PARS® simplifies logistics since diagnostics are done at point-of-care and the tissue container is automatically traced.
|
The PARS® Shortcut
PARS® delivers gold standard images for histology during surgery.
Tissue processing is not required.
Tissue processing is not required.
|
Upper part: tumor board – evaluate histo-pathology results and eventually schedule repeat surgery (15.5%* / 32.5%**) for positive surgical margins
Lower part: evaluate surgical margins intraoperatively and prevent repeat surgeries as left positive margins are identified intraoperatively with gold standard H&E histo-pathology diagnostics |
* Adams BJ, Zoon CK, Stevenson C, Chitnavis P, Wolfe L, Bear HD.
The role of margin status and reexcision in local recurrence following breast conservation surgery. Ann Surg Oncol. 2013;20(7):2250-2255 ** Piper, M.L., Wong, J., Fahrner-Scott, K. et al. Success rates of re-excision after positive margins for invasive lobular carcinoma of the breast. npj Breast Cancer 5, 29 (2019). https://doi.org/10.1038/s41523-019-0125-7 |
PARS® Applications under Development
|
PARS® MOHS SURGERY SOLUTION
Mohs skin cancer surgery requires multiple steps of tissue removal, each requiring frozen pathology confirmation. The PARS® Mohs system offers images of the same type in less than 5 min. This reduces the treatment time by approx. 25%.
PARS® IN-SURGERY SOLUTION
Positive surgical margins happen because cancer cells can not always be identified during the operation. PARS® in-surgery system will identify cancer tissue during the surgery. Re-operation becomes unnecessary.
|
About illumiSonics
illumiSonics develops, patents and commercializes PARS® advanced optical imaging systems
for a wide range of pre-clinical and clinical applications. Our proprietary PARS®
(photoabsorption remote sensing- previously known as Photoacoustic Remote Sensing) technology is a
revolution in optical imaging. We work with market leading partners to develop systems for specific applications.
for a wide range of pre-clinical and clinical applications. Our proprietary PARS®
(photoabsorption remote sensing- previously known as Photoacoustic Remote Sensing) technology is a
revolution in optical imaging. We work with market leading partners to develop systems for specific applications.
Recent News
2022 / 11
Dr. Parsin Haji Reza appointed Translational Medical Staff, Wills Eye Hospital
A bylaw approved by the Wills Eye Hospital Staff and the Philadelphia Board of Directors of City Trusts to appoint Dr. Haji Reza as a Translational Medical Staff for 2 years.
|
2022 / 03
Researchers' Corner 20/20 Innovation Vision
Dr. Parsin Haji Reza featured in CIL Researchers' Corner. The feature article focuses on Canada's Recovery - Research is Key: contributions, efforts, achievements, and challenges of our top research performers moving Canada into its recovery stage post pandemic
|
2022 / 03
Top 100 in Physics
Our paper published in Scientific Reports, "Functional and structural ophthalmic imaging using noncontact multimodal photoacoustic remote sensing microscopy and optical coherence tomography," is one of the top 100 most downloaded physics papers that were published in 2021.
|